Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

J&J is discontinuing the Phase 3 test of its drug, aticaprant, in major depressive disorder “due ... schizophrenia drug Invega and the nasal spray depression drug Spravato.

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Three of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, and one of RSU grants vests ratably in equal installments on the second, ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a study approval ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... hope to the estimated one-third of people with major depressive disorder who have not responded to existing therapies ...